Jeffrey A. Meyerhardt

机构：Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute · ORCID：0000-0002-1120-0898

发表论文 1095 篇 · 总被引 55203 次 · h-index 119

代表论文

• Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer (2026 · New England Journal of Medicine · 被引 20)
• Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib (2025 · JAMA Oncology · 被引 9)
• Tumor vessel phenotype in colorectal cancer microenvironment according to age at diagnosis (2026 · British Journal of Cancer · 被引 6)
• Metabolomic pattern of ultraprocessed food intake and its association with colorectal cancer risk (2025 · Gut · 被引 3)
• Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations: SWOG S2001. (2026 · Journal of Clinical Oncology · 被引 2)
• Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study (2026 · JCO oncology advances. · 被引 2)